1ST Biotherapeutics

1ST Biotherapeutics is a science-driven biopharmaceutical company focused on developing breakthrough therapies for neurodegenerative diseases, immuno-oncology, and rare diseases. Founded in 2016, 1ST Biotherapeutics has rapidly developed a series of first-class investigational therapies with clear disease-modifying mechanisms and excellent pharmacological properties. The company’s FB-101 is a c-Abl inhibitor under development for the treatment of Parkinson's disease and other neurodegenerative diseases associated with α-synucleinopathy.